Story perspectives

Pfizer Completes £2.55 Billion Haleon Stake Sale, Firm Now Independent

3/19/2025

40 3

Summary

Story summary

Pfizer has divested its final 7.3% stake in Haleon for about £2.55 billion ($3.3 billion), finalizing its separation.
The transaction included 618 million shares sold to institutional investors at £3.85 each, plus a £170 million off-market repurchase by Haleon.
Haleon, established from the 2019 merger of GSK and Pfizer's consumer health units, is now fully independent.
Following the sale, BlackRock will emerge as Haleon's largest shareholder, owning over 5% of the company.

History

Historical Context

Pfizer's divestment of its remaining 7.3% stake in Haleon marks the culmination of a significant trend in the pharmaceutical industry. This mirrors historical corporate separations, such as the 2004 spin-off of Hospira from Abbott Laboratories, emphasizing a shift towards focused operations and independence in the healthcare sector.

1 of 2

Story summary

Pfizer has divested its final 7.3% stake in Haleon for about £2.55 billion ($3.3 billion), finalizing its separation.
The transaction included 618 million shares sold to institutional investors at £3.85 each, plus a £170 million off-market repurchase by Haleon.
Haleon, established from the 2019 merger of GSK and Pfizer's consumer health units, is now fully independent.
Following the sale, BlackRock will emerge as Haleon's largest shareholder, owning over 5% of the company.

1 / 2